We surveyed Australian gay and bisexual men, assessing belief in HIV treatment as prevention (TasP) and support for early treatment. We identified the characteristics of participants who believed in TasP and supported early treatment using multivariate logistic regression. In 2013, 1316 men participated; 1251 participated in 2015. Belief in TasP increased from 2.6 % in 2013 to 13.1 % in 2015 (p < 0.001). The increase was most noticeable among HIV-positive men (from 9.7 % to 46.2 %). Support for early treatment increased from 71.8 % to 75.3 % (p = 0.02). Belief in TasP was associated with being HIV-positive, having a tertiary education, having recent condomless anal intercourse with casual male partners, and ever having taken post-exposure prophylaxis. Support for early HIV treatment was associated with being younger, living in New South Wales and being in paid employment. We recommend continued monitoring of the growing gap in belief about TasP between HIV-positive men and HIV-negative/untested men.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10461-016-1306-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of leveraging existing HIV primary health systems and community health workers for hypertension screening and treatment in Africa: An individual-based modeling study.
PLoS Med
January 2025
Institute for Global Health, University College London, London, United Kingdom.
Background: Cardiovascular disease (CVD) morbidity and mortality is increasing in Africa, largely due to undiagnosed and untreated hypertension. Approaches that leverage existing primary health systems could improve hypertension treatment and reduce CVD, but cost-effectiveness is unknown. We evaluated the cost-effectiveness of population-level hypertension screening and implementation of chronic care clinics across eastern, southern, central, and western Africa.
View Article and Find Full Text PDFTuberculosis treatment outcomes and associated factors among patients treated at Bosaso TB Hospital, Bosaso, Somalia: A five-year retrospective study.
PLoS One
January 2025
Administration Department, Ministry of Health (Puntland), Bosaso, Puntland, Somalia.
Introduction: Tuberculosis remains a major public health problem, primarily in low- and middle-income countries. Evaluating treatment outcomes and investigating factors associated with them are essential for the treatment and control of tuberculosis. Hence, this study aims to assess the TB treatment outcomes and associated factors in Bosaso, Puntland, Somalia.
View Article and Find Full Text PDFCommunity and familial dynamics influencing risk behavior for HIV acquisition among adolescent girls and young women in Uganda: Qualitative analysis using Protective Motivation Theory.
PLoS One
January 2025
Division of Global HIV & TB, US Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Background: In Uganda, adolescent girls', and young women's (AGYW-15-24 years) current HIV prevalence is fourfold compared with their male counterparts due to compounded social, economic, and environmental factors. Using the Protective Motivation Theory (PMT), we explored HIV-acquisition risk sources and perceived protective factors from AGYW and caregivers' perspective.
Materials And Methods: During 2018, we conducted a qualitative study guided by PMT to explore factors influencing HIV acquisition among AGYW.
Incidence and predictors of mortality among HIV positive children on anti-retroviral therapy in the selected health facilities of West Wollega Zone, Western Ethiopia: Retrospective cohort study.
PLoS One
January 2025
Departments of Public Health, Institute of Health Sciences, Wollega University, Ethiopia.
Introduction: The mortality rate among Human immunodeficiency Virus (HIV) who have started antiretroviral therapy (ART) continues to be increased in resource-limited countries, despite a decline in developed nations. Furthermore, research within this age group is limited and has not previously been conducted in the study area. Consequently, this study aimed to determine the incidence of mortality and its predictors among HIV-positive children who have been receiving ART at public health facilities in West Wollega.
View Article and Find Full Text PDFSynthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV.
Sci Adv
January 2025
Department of Chemistry, Stanford University, Stanford, CA 94305, USA.
Tigilanol tiglate (EBC-46) is a selective modulator of protein kinase C (PKC) isoforms that is Food and Drug Administration (FDA) approved for the treatment of mast cell tumors in canines with up to an 88% cure rate. Recently, it has been FDA approved for the treatment of soft tissue sarcomas in humans. The role of EBC-46 and, especially, its analogs in efforts to eradicate HIV, treat neurological and cardiovascular disorders, or enhance antigen density in antigen-targeted chimeric antigen receptor-T cell and chimeric antigen receptor-natural killer cell immunotherapies has not been reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!